Market Place
Sourcing Support
Bankrupt Zosano sells intradermal delivery tech to Emergex
18 Oct 2022 //
FIERCEPHARMA
Emergex Acquires Intradermal & Patch Drug Delivery Technology
12 Oct 2022 //
GLOBENEWSWIRE
Zosano sells off drug delivery tech that once enticed Novo Nordisk, Eli Lilly
12 Oct 2022 //
ENDPTS
After filing for bankruptcy, Zosano’s value more than halved
03 Jun 2022 //
ENDPTS
Zosano Pharma Files Voluntary Petition for Relief Under Chapter 11
02 Jun 2022 //
GLOBENEWSWIRE
Emergex Coats its CD8+ T cell Adaptive Vaccine onto Zosano`s Micro-Needle Patch
17 May 2022 //
GLOBENEWSWIRE
Zosano Pharma Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
Migraine patch developer Zosano Pharma suspends program
04 May 2022 //
BIZJOURNALS
After culling workforce, migraine biotech Zosano drops lead — and sole — program
02 May 2022 //
ENDPTS
Zosano Pharma Provides Corporate Update
29 Apr 2022 //
GLOBENEWSWIRE
Zosano Pharma Announces Reverse Stock Split Effective Today
11 Apr 2022 //
GLOBENEWSWIRE
Zosano`s migraines remain: Layoffs after FDA declines 2nd try
19 Mar 2022 //
MEDCITYNEWS
Zosano Pharma Reports Q4 and FY 2021 Financial Results
17 Mar 2022 //
GLOBENEWSWIRE
FDA Rejects Zosano`s Application For Zolmitriptan Microneedle System Again
22 Feb 2022 //
BENZINGA
Tiny pharma hits a new low with FDA refusing to review company`s to its CRL
22 Feb 2022 //
ENDPTS
Zosano Pharma Announces Pricing of $15.4M Public Offering
08 Feb 2022 //
GLOBENEWSWIRE
Zosano Pharma Announces Changes to Board of Directors; Appoints Cross
13 Dec 2021 //
GLOBENEWSWIRE
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29 Nov 2021 //
GLOBENEWSWIRE
Zosano Pharma Announces the Successful Formulation of a COVID-19
17 Nov 2021 //
GLOBENEWSWIRE
CSols Inc. Validates New LIMS at Zosano Pharma
26 Oct 2021 //
BUSINESSWIRE
Zosano Pharma Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
GLOBENEWSWIRE
Zosano Pharma Reports Second Quarter 2021 Financial Results
10 Aug 2021 //
GLOBENEWSWIRE
Zosano Pharma Announces Publication of Clinical Data Regarding the Long-term
26 May 2021 //
GLOBENEWSWIRE
Zosano Pharma Reports First Quarter 2021 Financial Results
12 May 2021 //
GLOBENEWSWIRE
Zosano Pharma Confirms Plan to Move Forward with Pharmacokinetic Study
26 Apr 2021 //
GLOBENEWSWIRE
Zosano Pharma Confirms NDA Resubmission Strategy Following Type A
22 Feb 2021 //
GLOBENEWSWIRE
Zosano Pharma Announces NDA Resubmission Plans Following Type A Meeting with FDA
01 Feb 2021 //
GLOBENEWSWIRE
Little Zosano takes another beating as the FDA slaps down their application
21 Oct 2020 //
ENDPTS
Zosano Pharma Receives Preliminary FDA Communication on Qtrypta™ NDA
30 Sep 2020 //
GLOBENEWSWIRE
Zosano Pharma Announces Proposed Public Offering of Common Stock
31 Aug 2020 //
GLOBALNEWSWIRE
Zosano Pharma Announces Partnership Agreement with EVERSANA
06 Aug 2020 //
GLOBENEWSWIRE
Zosano Pharma Announces the Appointment of Christine Matthews as CFO
01 May 2020 //
GLOBENEWSWIRE
Zosano Pharma Announces Pricing of $8.0 Million Public Offering
12 Feb 2020 //
GLOBE NEWSWIRE
Zosano Announces FDA Submission of NDA for Qtrypta
23 Dec 2019 //
GLOBE NEWSWIRE
Zosano readies contract manufacturers for pre-approval inspections
25 Nov 2019 //
IN PHARMATECHNOLOGIST
Zosano evaluates C213 in Phase II/III cluster headache trial
25 Oct 2019 //
CLINICALTRIALSARENA
Zosano Pharma Initiates Phase 2/3 Clinical Study in Second Late Stage Program
24 Oct 2019 //
BIOSPACE
Zosano Pharma CEO passes baton down to successor James Sapirstein takes the helm
12 Oct 2019 //
ENDPTS
